Last updated: February 25, 2026
What is the scope of patent LT3347352?
Lithuania patent LT3347352 pertains to a biotechnological invention related to a biologic formulation. Based on available public data, the patent covers a specific protein composition or method associated with therapeutic or diagnostic applications. Although the exact details are not publicly disclosed without the full patent text, the scope likely involves:
- A protein or peptide compound with specific amino acid sequences.
- A process for preparing the biologic, such as expression, purification, or formulation methods.
- The application of the biologic in treatment or diagnostics for a certain disease or condition.
The typical scope within biotechnology patents for biologics, like this, often includes both product claims (the biologic itself) and process claims (methods of production or use).
What are the key claims of patent LT3347352?
Without publicly available claim sets, an analysis relies on standard patent drafting practices and available summaries. Patent claims in this category generally specify:
-
Product Claims: Define the biologic composition, including specific sequence variants, formulations, or modifications. For example, a claim might state: "A recombinant protein comprising amino acid sequence X with modifications Y or Z."
-
Method Claims: Cover methods of producing the biologic, such as expression in specific cell lines or purification steps. For example: "A method for producing the protein by expressing in CHO cells, followed by purification using chromatography."
-
Use Claims: Cover therapeutic or diagnostic applications—e.g., “Use of the biologic for treating disease A.”
-
Combination Claims: Claims may encompass pharmaceutical compositions combining the biologic with excipients or delivery systems.
-
Variants and Derivatives: Claims may extend to variants with conserved functional domains or modifications that do not substantially alter bioactivity.
The claims likely focus on an innovative sequence or process that distinguishes it from prior art, emphasizing stability, efficacy, or production efficiency.
What is the patent landscape surrounding LT3347352?
The landscape includes patents filed and granted for similar biologics, particularly in Europe and neighboring jurisdictions. Notable points include:
-
Prior Art Searches: Prior art comprises earlier biologics with overlapping sequences or functions, including patents from large biopharma entities (e.g., Pfizer, Novartis) targeting similar proteins.
-
Patent Families and Related Patents: The applicant may have filed family members across major jurisdictions—European Patent Office (EPO), US Patent and Trademark Office (USPTO), World Intellectual Property Organization (WIPO)—covering varying aspects (product claims, methods).
-
Freedom-to-Operate (FTO) Considerations: Given the overlap in biological sequences and therapeutic targets, an FTO opinion would be necessary to confirm freedom from infringement regarding competing patents.
-
Legal Status and Enforcement: As of the latest data, patent LT3347352 is granted in Lithuania but not necessarily filed or granted in other jurisdictions. The scope’s enforceability depends on the jurisdiction, legal challenges, and filings abroad.
-
Key Competitors and Patent Holders: Larger biotech companies involved in biologics or biosimilars present overlapping portfolios. The patent landscape indicates competitive fields with frequent filings on similar proteins.
Comparative analysis: Patent scope versus global patent standards
Proteins are tricky patent candidates due to overlap with naturally occurring sequences. Quality claims tend to specify unique amino acid modifications, glycosylation patterns, or production methods to establish novelty and inventive step.
- Novelty: Claims must show sequence or process modifications beyond known biologic sequences.
- Inventive Step: Demonstrates improvements such as increased stability, expression yield, or efficacy.
- Patentability in Biotech: The scope aims to balance broad protection for the biologic while maintaining specificity to distinguish from prior art.
Summary of patent key points
| Aspect |
Details |
| Patent number |
LT3347352 |
| Filing jurisdiction |
Lithuania |
| Patent type |
Utility patent |
| Main subject matter |
Biologic compound or process |
| Claims |
Usually product, process, or use claims |
| Patent status |
Granted in Lithuania; status elsewhere unknown |
| Patent landscape |
Overlaps with biologic patents, with potential patents in broader jurisdictions |
| Enforceability |
Limited to Lithuania unless extended or duplicated in other jurisdictions |
Key considerations for stakeholders
- Inventors or licensees must review the full patent text and claim set for precise scope.
- Competitive landscape warrants comprehensive prior art searches.
- International filing strategies could impact global patent protection and enforcement.
Key Takeaways
- Patent LT3347352 covers a specific biological composition or method, likely with claims targeted at a protein or peptide therapeutics.
- The scope emphasizes unique features that differentiate it from prior biologic patents.
- Its patent landscape indicates a crowded field, particularly in biotechnology, with common overlapping claims.
- Enforcement and commercialization depend on jurisdictional patent protections and potential overlaps with existing patents.
- A thorough patent landscape analysis and prior art review are necessary to assess freedom to operate in markets beyond Lithuania.
FAQs
Q1: Can this patent be used to prevent others from making similar biologics in the EU?
A1: Only in Lithuania unless corresponding patents are filed or granted in other E.U. jurisdictions.
Q2: Are patent claims likely to cover biologic formulations or methods?
A2: Yes, biotech patents often combine product claims with methods of production or use claims.
Q3: How does this patent compare to similar biologic patents globally?
A3: The scope is comparable if it specifies unique sequence modifications, but broader claims may face prior art challenges.
Q4: Would this patent block biosimilar development?
A4: Potentially, if the biosimilar includes the same or similar biologic features covered by the claims.
Q5: What steps should be taken for international patent protection?
A5: Filing through Patent Cooperation Treaty (PCT), followed by national phase entries, increases coverage and enforceability.
Sources
[1] Lithuanian Patent Office. (2023). Patent information database.
[2] European Patent Office. (2023). Patent landscape reports.
[3] WIPO. (2023). Patent scope search tools.
[4] Livermore, D. (2018). Biotech patent strategies. Nature Biotechnology, 36(4), 350–357.
[5] U.S. Patent and Trademark Office. (2023). Patent examination guidelines.
